MarketBeat

Mon, September 21, 2026 at 6:02 AM EDT 6 min read

Key Points

• Interested in Cencora, Inc.? Here are five stocks we like better.

• Specialty pharmaceuticals and MSOs are central to Cencora's growth strategy, with particular emphasis on retina and oncology practices. Management expects the MSO business to remain profitable, expand through physician and tuck-in additions, and become a larger part of the company's mix.

• Cencora will support clinical trials through World Courier and its physician networks but does not plan to acquire a contract research organization. The company sees its logistics and practice-management capabilities as complementary to CROs and pharmaceutical manufacturers.

• Capital-allocation priorities remain focused on core investment, smaller acquisitions, opportunistic share repurchases, dividend growth aligned with earnings, and maintaining a strong balance sheet. Management also reaffirmed its ongoing Walgreens relationship, citing a U.S. contract through 2029 and a Boots agreement through 2031.

• Cardinal Health Earnings: Can Perfection Get Priced In Twice?

Cencora (NYSE:COR) executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens.

Chief Executive Officer Bob Mauch said Cencora's growth is being supported by pharmaceutical innovation, demographic trends and the company's long-standing investments in specialty distribution and related services. He described pharmaceuticals as a cost-effective healthcare intervention and said the company is positioned to help manufacturers bring complex products to market while supporting providers and patients.

→ 2 Stocks Breaking Out Post-FOMC With One Thing in Common

• McKesson's Compounding Keeps Adding Up

"What is the driver of that growth is really the positioning that we have within the specialty pharmaceutical market," Mauch said. "You have this amazing innovation that's happening in pharma."

Mauch said the company has spent more than two decades investing, competing and building capabilities in specialty care. Those capabilities include specialty distribution, group purchasing organization services and medical specialty organizations, or MSOs. He said Cencora aims to provide support in the background so providers can focus on patient care.

New CFO Sees Broad Services Platform

→ Generac Plugs into Amazon for an $8B AI-Powered Deal

• Active ETFs Surge Past Passive, and These Are in the Lead